--- title: "PHQ-9 screening in US primary care: flow and follow-up" description: "USPSTF gives depression screening a B grade for adults — the operational gap is what happens after a positive PHQ-9. Build the follow-up path before you…" url: https://www.getarbol.com/en/blog/depression-screening-primary-care-us/ lang: en --- # PHQ-9 screening in US primary care: flow and follow-up USPSTF gives depression screening a B grade for adults — the operational gap is what happens after a positive PHQ-9. Build the follow-up path before you scale. [**Veronica Tobon** Medical Advisor, Clínica Sierra Vista](https://www.getarbol.com/en/blog/authors/veronica-tobon/) April 24, 2026 10 min read The U.S. Preventive Services Task Force (USPSTF) recommends screening adults for depression — including pregnant and postpartum persons and older adults — with a Grade B. The Patient Health Questionnaire-9 (PHQ-9) is the instrument most US primary care practices already have in the EHR. The guide problem is not whether to screen; it is building a flow that scores the instrument, routes positive results to diagnostic evaluation, and follows people who never return for the next step. Screening without follow-up is documentation, not care. Key takeaways - USPSTF (June 20, 2023) recommends screening for depression in adults, including pregnant and postpartum persons and older adults (Grade B); evidence for screening suicide risk in asymptomatic adults is insufficient (I statement). - USPSTF’s pathway to benefit requires that persons who screen positive are evaluated further for diagnosis and, if appropriate, provided or referred for evidence-based care. - CDC’s NHANES depression screener documentation describes the PHQ-9 as nine symptom items scored 0–3 each (total 0–27), covering the past two weeks, with an impairment item when any symptom is endorsed. - USPSTF found no evidence on optimal screening frequency — pragmatic practice is to screen adults not previously screened and use clinical judgment for higher-risk intervals. ## What USPSTF actually recommends — and what it does not The [USPSTF final recommendation statement of June 20, 2023](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults) is the clinical north star for US primary care depression screening. For adults 19 and older, including pregnant and postpartum persons and adults 65 and older, who do not already have a diagnosed mental health disorder and are not showing recognized signs or symptoms of depression or suicide risk, the Task Force recommends screening for major depressive disorder (MDD) — Grade **B**. For screening for suicide risk in that asymptomatic adult population, the Task Force concludes evidence is insufficient — Grade **I**. Two sentences in the recommendation do more operational work than the grade letter. First, the pathway to benefit: persons who screen positive must be evaluated further for diagnosis and, if appropriate, provided or referred for evidence-based care. Second, on frequency: the USPSTF found no evidence on optimal screening intervals; a pragmatic approach is to screen adults who have not been screened previously and use clinical judgment — considering risk factors, comorbid conditions, and life events — for additional screening, with ongoing assessment during pregnancy and postpartum as a reasonable approach. The importance section grounds why practices invest: in 2019, **7.8%** (19.4 million) of US adults experienced at least one major depressive episode, and **5.3%** (13.1 million) experienced an episode with severe impairment, per the sources the USPSTF cites. Suicide was described as the 10th-leading cause of death in US adults in the recommendation’s importance discussion (2019 data). Those are population figures — your practice’s job is the pathway, not the prevalence headline. Treatment context in the clinician summary includes psychotherapy, pharmacotherapy, and collaborative care models that use care managers to link primary care clinicians, patients, and mental health specialists. Screening that cannot connect to any of those paths fails the Task Force’s own benefit logic. ## What the PHQ-9 is measuring in the exam room The PHQ-9 is a brief, self-report depression severity instrument validated for primary care. CDC’s [NHANES Mental Health — Depression Screener documentation (DPQ_L)](https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2021/DataFiles/DPQ_L.htm) describes how the federal survey administers it: nine symptom questions about the past two weeks, each scored **0 to 3** for “not at all,” “several days,” “more than half the days,” and “nearly every day,” producing a total from **0 to 27** when responses are complete. An additional functional impairment question is asked if any symptom is endorsed. The documentation cites Kroenke and colleagues’ validation work ([PubMed record for the 2001 JGIM paper](https://pubmed.ncbi.nlm.nih.gov/11556941/)) for pre-defined cut-points used to assess major depression and severity. Operationally, primary care teams should treat the PHQ-9 as a **screen and severity tracker**, not as a stand-alone diagnosis. A positive or elevated score triggers diagnostic evaluation — clinical interview, differential diagnosis, safety assessment — by a qualified clinician. Item 9 (thoughts of being better off dead or of self-harm) requires an immediate safety pathway, not a “follow up next visit” sticky note. Practices that auto-score the PHQ-9 in the EHR without routing item-9 positives to same-day clinical review have built a liability machine, not a screening program. USPSTF + CDC instrument framing The recommendation is clear; the instrument is scored 0–27 Grade B Screen adults (incl. perinatal, older adults) for depression USPSTF, June 2023 0–27 PHQ-9 total score range (nine items × 0–3) CDC NHANES DPQ_L documentation 7.8% US adults with ≥1 major depressive episode (2019, USPSTF-cited) USPSTF recommendation importance section ## A primary care screening flow that survives Monday A flow that only works when the clinic is quiet does not work. Build for the overloaded Tuesday. 1. 1 Offer the instrument before the clinician enters Tablet, paper, or portal completion in the past two weeks — same nine items, scored consistently. 2. 2 Auto-score and flag item 9 Any nonzero item-9 response routes to same-day clinical safety review before the patient leaves. 3. 3 Clinician reviews score in context Positive or elevated scores trigger diagnostic evaluation — not automatic medication. 4. 4 Document the plan and the owner Treat in clinic, refer, collaborative care — with a named next appointment or outreach date. 5. 5 Close the loop after the visit Track whether the diagnostic visit, therapy start, or psychiatry referral actually occurred. Where flows break Three failure points after a positive screen Score Instrument completed, nobody looks EHR stores a number; the visit proceeds as if screening never happened. Plan Plan written, slot never booked ‘Refer to behavioral health’ without a date is a wish, not a plan. Loop Patient does not return No outreach for missed diagnostic or therapy visits — the Grade B benefit evaporates. Staff roles should be explicit. Medical assistants can administer and score. Clinicians own diagnosis and treatment decisions. Care managers or referral coordinators own the loop after a positive screen. Reception owns outreach when a scheduled follow-up is missed. If every role “kind of” owns follow-up, nobody does. ## Follow-up is where the Grade B is won or lost USPSTF’s pathway language is the audit standard: screen → further evaluation → evidence-based care when appropriate. Practices should measure three conversion rates, not just screening completion percentage: 1. **Screened among eligible visits** — are you offering the instrument? 2. **Evaluated among positive screens** — did diagnostic evaluation happen within a defined window? 3. **Engaged among those needing treatment** — did therapy, medication management, or collaborative care actually start? Missed follow-up visits are an access problem as much as a clinical one. Confirmation calls or messages, easy reschedule, and outreach when someone no-shows a behavioral health intake are part of the depression pathway — not a separate “marketing” workstream. The same front-office discipline that protects ordinary appointment access protects screening benefit. Collaborative care, which the USPSTF clinician summary flags via Community Preventive Services Task Force recommendations, is one evidence-aligned way to keep follow-up inside primary care rather than hoping specialty waitlists clear. Even without a full collaborative care build, a weekly registry review of open positive screens is the minimum viable follow-up structure. After a positive PHQ-9 A finite follow-up clock Same day Safety + diagnostic plan Item-9 positives get same-day review; others get a scheduled evaluation path before leaving. ≤14 days Evaluation completed or actively outreached If the diagnostic visit is missed, outreach starts — do not wait for the next annual. ≤30 days Treatment engagement check Confirm therapy start, med follow-up, or collaborative care enrollment — or document decline. Fuente: Operationalizing USPSTF pathway-to-benefit language ## Perinatal depression overlaps this flow — it does not replace it USPSTF’s Grade B explicitly includes pregnant and postpartum persons. Risk factors listed in the clinician summary for perinatal depression include life stress, low social support, history of depression, partner dissatisfaction, and history of abuse. The recommendation also notes rising self-reported depression during pregnancy in PRAMS data cited there (11.6% in 2016 to 14.8% in 2019). That does not mean one six-week postpartum PHQ-9 finishes the job. Our related analysis on [postpartum depression screening in primary care](https://www.getarbol.com/en/blog/postpartum-depression-screening-primary-care/) focuses on the coverage window and visit timing problem: Medicaid’s postpartum coverage expansion does not automatically create a screening calendar. Adult screening workflows and perinatal workflows should share instruments and safety paths, then diverge on cadence and obstetric coordination. Do not build two disconnected PHQ-9 programs that neither talk to the EHR registry nor share escalation rules. ## What your practice can do this week This is a guide, not a product pitch. The work is operational. PHQ-9 pathway checklist - Confirm USPSTF Grade B screening is offered to eligible adults without known depression diagnoses Include perinatal and older adult visits in the same policy. - Verify EHR scoring matches the nine-item 0–3 structure (total 0–27) Align with CDC/NHANES instrument description and Kroenke validation references. - Write an item-9 same-day safety protocol with a named owner Test it with a drill, not only a policy PDF. - Define ‘positive screen → evaluation’ with a maximum lag in days USPSTF requires further evaluation — put a clock on it. - Build a registry of open positives and missed follow-ups Review weekly; outreach is part of screening benefit. - Separate suicide-risk screening experiments from depression screening operations USPSTF I statement means do not pretend the evidence base is settled for asymptomatic universal suicide screening. Quick clarifications Does a PHQ-9 diagnose major depression by itself? No. It is a screening and severity instrument. Diagnosis requires clinical evaluation. How often should we screen? USPSTF found no optimal frequency. Pragmatic approach: screen those not previously screened; use judgment for higher-risk intervals; reassess during pregnancy and postpartum. What about suicide risk screening for everyone? USPSTF concludes evidence is insufficient (I) for screening asymptomatic adults for suicide risk. Maintain clinical vigilance and safety protocols when symptoms or PHQ item 9 appear. For US practice operations more broadly, the market context lives on [/en/united-states/](https://www.getarbol.com/en/united-states/). Depression screening earns its Grade B only when the pathway after the score is as reliable as the checkbox that captured it. Disclaimer This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. ## Keep reading United States **Keep reading** United States Women's health ### [Postpartum depression screening: what the evidence supports](https://www.getarbol.com/en/blog/postpartum-depression-screening-primary-care/) Most postpartum depression screening still happens at one six-week visit, even though nearly every state now covers a full year of Medicaid after birth. Emilia Santander Jun 3, 2026 10 min read Read the article ### More to read United States Primary care ### [GLP-1 coverage in 2026: what it means for primary care](https://www.getarbol.com/en/blog/glp1-coverage-primary-care/) Medicare, Medicaid and employer plans now cover GLP-1 drugs under different rules and timelines. Here is what that patchwork means for your practice. Norbelys Chirinos May 20, 2026 9 min read United States Primary care ### [Medicare Annual Wellness Visit reminders that convert](https://www.getarbol.com/en/blog/medicare-annual-wellness-visit/) US Medicare covers a yearly Wellness visit at $0 with assignment — if your practice qualifies people, books the right visit type, and follows up. David Lara Jun 19, 2026 10 min read United States Regulation ### [TCPA Consent for Appointment Reminders: What Actually Changed](https://www.getarbol.com/en/blog/tcpa-appointment-reminders-compliance/) The FCC's TCPA consent rules for reminder calls and texts are still shifting. Here is what your practice's intake process needs to get right now. Samuel Giraldo May 13, 2026 10 min read ## Let’s look at your population in Arbol. A 30-minute video call with our team, using your cases: your contract, your patients and your channels. You leave with a first read of your population, your contract and your utilization rates. [Book a demo](https://cal.com/tomas-giraldo-pdfbl9/30-min-arbol-ai-demo) [Message us on WhatsApp](https://wa.me/573185230045?text=Hello%2C%20I%27d%20like%20to%20learn%20more%20about%20Arbol%20for%20my%20organization.) [**Colombia**](https://www.getarbol.com/en/colombia/), in operation · Built for Latin America --- **Arbol AI** — AI agents for clinics and healthcare providers: they answer and reach patients by phone, WhatsApp, SMS, email and web chat, book their appointments 24/7 and keep a record of every conversation. - Original page: - Book a demo: · Pricing: - Agent index: · Support: